Literature DB >> 22075401

Neurohormonal and cytokine fluctuations following transcatheter closure for an atrial septal defect.

Aikaterini C Chamakou1, Eleni Dede, Antonia Moutafi, Vassileios Thanopoulos, Stavros Chryssanthopoulos, Sophia Loukopoulou, Christos Pitsavos, Christodoulos Stefanadis, Constantinos H Davos.   

Abstract

INTRODUCTION: Inflammation and neurohormonal activation are considered to be involved in the development of earlier and/or later complications in congenital heart disease patients, even after a successful repair of the lesion. It is not yet clarified what is the role of the therapeutic interventions in the occurrence of such a response and how it could be associated with possible postoperative complications. AIM: We sought to assess the inflammatory and neurohormonal response to transcatheter closure of secundum type atrial septal defects (ASD) over a six-month follow-up period. We also evaluated the association between the respective markers and catheterization data as well as echocardiographic measurements.
METHODS: Plasma concentrations of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), interleukin-10 (IL-10), N-terminal-proatrial natriuretic peptide (NT-proANP) and N-terminal-probrain natriuretic peptide (NT-proBNP) were assessed and echocardiographic measurements were performed in twenty-eight patients with atrial septal defect prior to, and at the first, second and sixth months post transcatheter closure. Thirty-three age-matched healthy volunteers were also enrolled.
RESULTS: IL-6 plasma levels, although higher preoperatively, [physical logarithm (ln) IL-6: 3.37±0.66 vs 2.92±0.44 pg/ml, p=0.015], reached control levels postoperatively, at the end of the third month, whereas TNF-α and IL-10 were not influenced by the procedure. NT-proANP levels were elevated preoperatively compared to the control group (ln NT-proANP 3.78±0.572 vs 3.48±0.30, p=0.031), with a further significant increase during the 1st month (ln NT-proANP 3.78±0.572 vs 4.2±0.42, p=0.006), following the pattern of the left atrial volume enlargement, and remained high even 6 months after the procedure .On the other hand, the initially normal concentrations of NT-proBNP, after a transient significant increase during the first month postoperatively (ln NT-proBNP 3.56±0.94 vs 4.58±0.91, p<0.0001) returned to the controls' levels at the end of the third month. Preoperative concentrations of NT-proANP positively correlated with NT-proBNP concentrations and pulmonary to systemic flow ratio (Qp/Qs).
CONCLUSIONS: Transcatheter closure could improve, on a mid- term basis, the inflammatory process but natriuretic peptides' secretion continues in parallel with left atrial volume increase. Further follow up is required to determine the long-term progress of the inflammatory and neurohormonal response to the procedure.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22075401     DOI: 10.1016/j.cyto.2011.10.002

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  3 in total

1.  Hypoalbuminaemia predicts outcome in adult patients with congenital heart disease.

Authors:  Aleksander Kempny; Gerhard-Paul Diller; Rafael Alonso-Gonzalez; Anselm Uebing; Isma Rafiq; Wei Li; Lorna Swan; James Hooper; Jackie Donovan; Stephen J Wort; Michael A Gatzoulis; Konstantinos Dimopoulos
Journal:  Heart       Date:  2015-03-03       Impact factor: 5.994

2.  Evolution of blood biomarker levels following percutaneous atrial septal defect closure in adults.

Authors:  Laurie W Geenen; Lucas Uchoa de Assis; Vivan J M Baggen; Jannet A Eindhoven; Judith A A E Cuypers; Eric Boersma; Jolien W Roos-Hesselink; Annemien E van den Bosch
Journal:  Int J Cardiol Heart Vasc       Date:  2020-07-21

3.  Increased inflammatory markers in adult patients born with an atrial septal defect.

Authors:  Anne-Sif Lund Schram; Anna Sellmer; Camilla Nyboe; Martin Sillesen; Vibeke Elisabeth Hjortdal
Journal:  Front Cardiovasc Med       Date:  2022-08-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.